Novartis AG Common Stock (NVS)

Total Non-Current Liabilities

$48.34B

Quarterly · Period ending: · USD

NVS logo

NVS Total Non-Current Liabilities

Latest reported$48.34B
NVS Quarterly Total Non-Current Liabilities ($6.64B → $48.34B)
High-resolution chart · PNG

NVS total non-current liabilities history

Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

Novartis AG Common Stock Total Non-Current Liabilities — Quarterly (USD)
Period endingTotal Non-Current Liabilities (USD)
48,339,194,000
48,231,000,000
41,742,072,000
30,537,000,000
30,627,000,000
29,870,000,000
29,428,000,000
31,951,000,000
27,991,000,000
25,290,000,000
30,683,939,583
26,059,000,000
27,139,000,000
29,550,000,000
33,686,081,520
29,406,000,000
32,258,000,000
33,707,000,000
37,854,000,000
34,392,000,000
40,254,000,000
41,003,000,000
42,464,000,000
43,286,000,000
40,496,000,000
40,826,000,000
34,597,850,467
35,153,000,000
34,679,000,000
34,512,000,000
37,264,000,000
36,648,000,000
37,214,000,000
36,090,000,000
35,449,000,000
37,223,000,000
37,625,000,000
38,010,000,000
33,024,000,000
34,337,000,000
32,633,000,000
32,742,000,000
30,726,000,000
27,984,000,000
27,192,000,000
29,438,000,000
27,570,000,000
27,337,000,000
27,695,000,000
30,236,000,000
25,414,000,000
26,603,000,000
27,056,000,000
27,494,000,000
30,946,000,000
32,155,000,000
29,331,000,000
28,854,000,000
28,408,000,000
29,406,000,000
29,286,000,000
29,662,000,000
28,891,000,000
30,753,000,000
23,279,000,000
23,147,000,000
18,573,000,000
19,471,000,000
18,428,000,000
16,752,000,000
11,358,000,000
11,329,000,000
12,111,000,000
9,996,000,000
9,415,000,000
9,942,000,000
10,977,000,000
10,273,000,000
10,480,000,000
11,957,000,000
12,008,000,000
9,504,000,000
9,240,000,000
10,475,000,000
10,007,000,000
8,862,000,000
9,470,000,000
9,426,000,000
9,401,000,000
9,521,000,000
9,478,000,000
9,542,000,000
9,398,000,000
9,108,000,000
8,440,000,000
6,968,000,000
7,023,000,000
6,160,000,000
5,788,000,000
5,863,000,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.